VR Adviser’s enGene Therapeutics ENGN Stock Holding History

VR Adviser’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32.5M	Hold	4,771,414	–	–	1.21%	22
2025 Q4	$43.1M	Sell	4,771,414 -275,000	-5%	-$2.2M	2.13%	15
2025 Q3	$34.5M	Hold	5,046,414	–	–	1.94%	17
2025 Q2	$18.4M	Hold	5,046,414	–	–	1.38%	21
2025 Q1	$22.6M	Hold	5,046,414	–	–	1.92%	15
2024 Q4	$33.6M	Buy	5,046,414 +1,480,573	+42%	+$11.5M	2.3%	16
2024 Q3	$23.5M	Buy	3,565,841 +739,858	+26%	+$5.5M	1.23%	23
2024 Q2	$26.6M	Buy	2,825,983 +260,142	+10%	+$3.34M	1.7%	19
2024 Q1	$43.5M	Buy	+2,565,841	New	+$31.4M	2.07%	16

Other funds holding ENGN

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

VR Adviser's ENGN Position: Q1 2026 in Review

VR Adviser held its enGene Therapeutics (ENGN) position steady in Q1 2026 at 4,771,414 shares worth $32.5M. The position accounts for 1.21% of the portfolio, ranked #22.

VR Adviser first reported a position in ENGN in Q1 2024 and has held it in 9 quarters since. The position peaked at $43.5M in Q1 2024. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

VR Adviser held 4,771,414 shares of enGene Therapeutics worth $32.5M as of Q1 2026.
VR Adviser left its enGene Therapeutics share count unchanged in Q1 2026.
enGene Therapeutics made up 1.21% of VR Adviser's portfolio in Q1 2026, its #22 holding.
VR Adviser first reported a position in enGene Therapeutics in Q1 2024 and has held it in 9 quarters since.
VR Adviser's enGene Therapeutics position peaked at $43.5M in Q1 2024.
61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on VR Adviser's 13F filing for Q1 2026, filed 15 May 2026.